Phenylephrine

IMMPHENTIV injection 100 mcg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock. IMMPHENTIV injection 100 mcg/mL is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.

IMMPHENTIV Injection 100 mcg/mL: Do NOT dilute prior to administration. Dosing for Perioperative Hypotension - Intravenous bolus administration: 50 mcg to 250 mcg. Phenylephrine Hydrochloride Injection 10 mg/mL: MUST BE DILUTED before administration. Intravenous continuous infusion: 0.5 mcg/kg/minute to 1.4 mcg/kg/minute titrated to effect. Dosing for Patients with Vasodilatory Shock Intravenous continuous infusion: 0.5 mcg/kg/minute to 6 mcg/kg/minute titrated to effect

The use of IMMPHENTIV 100 mcg/mL and Phenylephrine Hydrochloride Injection 10 mg/mL is contraindicated in patients with: Hypersensitivity to the products or any of their components Hypersensitivity to the products or any of their components

Severe bradycardia and decreased cardiac output: Extravasation: during intravenous administration may cause necrosis or sloughing of tissue. Concomitant use with oxytocic drugs: pressor effect of sympathomimetic pressor amines is potentiated. Allergic-type reactions with Phenylephrine Hydrochloride Injection 10 mg/mL: Sulfite

The following adverse reactions associated with the use of phenylephrine hydrochloride were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

Agonistic effects with monoamine oxidase inhibitors (MAOI), β-adrenergic blocking agents, α-2 adrenergic agonists, steroids, tricyclic antidepressants, norepinephrine transport inhibitors, ergot alkaloids, centrally-acting sympatholytic agents and atropine sulfate. Antagonistic effects on and by α-adrenergic blocking agents

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Phenylephrine Hydrochloride injection, USP, 10 mg/mL, is supplied as follows: NDC 0641-6142-25: 10 mg in 1 mL fill (10 mg/mL) in 2 mL single-dose vials packaged in cartons containing 25 vials per carton NDC 0641-6188-10: 50 mg in 5 mL (10 mg/mL) Pharmacy Bulk Package vials packed in cartons containing 10 vials per carton NDC 0641-6189-10: 100 mg in 10 mL (10 mg/mL) Pharmacy Bulk Package vials packed in cartons containing 10 vials per carton Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Protect from light.